Overview

Blinatumomab Maintenance After Allo-HSCT

Status:
NOT_YET_RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.

Phase:

PHASE2

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

blinatumomab